PharmaShots | Incisive News in 3 Shots

Subscribe Now

Formycon AG

Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA

Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA

November 27, 2023

Formycon AG and its License Partner Klinge Biopharma GmbH Report the BLA Submission of FYB203 (biosimilar, aflibercept) to the US FDA

Formycon AG and its License Partner Klinge Biopharma GmbH Report the BLA Submission of FYB203 (biosimilar, aflibercept) to the US...

June 29, 2023

Formycon AG Reports Preliminary P-III Trial (MAGELLAN-AMD) Results FYB203, a Proposed Biosimilar to Eylea

Formycon AG Reports Preliminary P-III Trial (MAGELLAN-AMD) Results FYB203, a Proposed Biosimilar to Eylea

February 6, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us